| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 49 companies in the Life Sciences Tools & Services industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 7, 2017 | BIO Bio-Rad Laboratories, Inc. | Crowley Michael60 | EVP, Gbl Commercial Operations | Sell | 300 | $196.13 | $58,840.29 | -9.8% | |
| Mar 6, 2017 | CRL Charles River Laboratories International, Inc. | Barbo William D66 | Corporate Executive VP &CCO | Sell | 12,548 | $87.78 | $1,101,409.09 | -1.7% | |
| Mar 6, 2017 | CRL Charles River Laboratories International, Inc. | Barbo William D66 | Corporate Executive VP &CCO | Sell | 1,900 | $87.90 | $167,013.50 | -1.2% | |
| Mar 6, 2017 | TMO Thermo Fisher Scientific Inc. | Williamson Stephen68 | Sr. VP And CFO | Sell | 2,500 | $158.71 | $396,775.00 | -5.8% | |
| Mar 6, 2017 | BIO Bio-Rad Laboratories, Inc. | Magni Giovanni | EVP, Chief Strategy Officer | Sell | 4,498 | $195.93 | $881,299.57 | -15.1% | |
| Mar 6, 2017 | TMO Thermo Fisher Scientific Inc. | Loewald Thomas W | Senior Vice President | Sell | 4,049 | $158.71 | $642,616.79 | -8.6% | |
| Mar 6, 2017 | TMO Thermo Fisher Scientific Inc. | Hoogasian Seth H | Sr. VP And Gen. Counsel | Sell | 3,142 | $158.71 | $498,666.82 | -9.2% | |
| Mar 3, 2017 | CRL Charles River Laboratories International, Inc. | Smith David Ross63 | Corporate EVP, CFO &CAO | Sell | 3,890 | $88.12 | $342,805.40 | -1.4% | |
| Mar 3, 2017 | CRL Charles River Laboratories International, Inc. | Smith David Ross63 | Corporate EVP, CFO &CAO | Sell | 7,750 | $87.94 | $681,530.64 | -1.3% | |
| Mar 3, 2017 | OPK Opko Health, Inc. | Frost Phillip Md Et Al48 | CEO &Chairman | Buy | 8,600 | $7.43 | $63,894.50 | - | |
| Mar 2, 2017 | OPK Opko Health, Inc. | Frost Phillip Md Et Al48 | CEO &Chairman | Buy | 94,800 | $7.53 | $713,787.12 | - | |
| Mar 2, 2017 | BIO Bio-Rad Laboratories, Inc. | Goetz John | EVP, Chief Operating Officer | Sell | 3,500 | $196.34 | $687,188.60 | -5.7% | |
| Mar 1, 2017 | CRL Charles River Laboratories International, Inc. | Bertolini Robert J | Director | Sell | 5,255 | $87.53 | $459,988.10 | -0.6% | |
| Mar 1, 2017 | CRL Charles River Laboratories International, Inc. | Bertolini Robert J | Director | Sell | 6,735 | $88.00 | $592,701.71 | -1.3% | |
| Feb 28, 2017 | DHR Danaher Corp /de/ | Ellis Brian W62 | Senior Vice President - GC | Sell | 983 | $86.00 | $84,533.09 | -13.7% | |
| Feb 28, 2017 | CRL Charles River Laboratories International, Inc. | Foster James C77 | Chairman, President And CEO | Sell | 5,038 | $87.31 | $439,887.11 | - | |
| Feb 28, 2017 | CRL Charles River Laboratories International, Inc. | Foster James C77 | Chairman, President And CEO | Sell | 3,772 | $88.03 | $332,064.28 | - | |
| Feb 28, 2017 | CRL Charles River Laboratories International, Inc. | Foster James C77 | Chairman, President And CEO | Sell | 5,081 | $87.61 | $445,166.58 | - | |
| Feb 28, 2017 | CRL Charles River Laboratories International, Inc. | Foster James C77 | Chairman, President And CEO | Sell | 1,270 | $88.48 | $112,375.45 | - | |
| Feb 28, 2017 | CRL Charles River Laboratories International, Inc. | Foster James C77 | Chairman, President And CEO | Sell | 4,910 | $87.09 | $427,614.78 | - | |
| Feb 27, 2017 | DHR Danaher Corp /de/ | Lalor Angela S | SVP, Human Resources | Sell | 6,044 | $86.20 | $521,016.98 | -10.0% | |
| Feb 27, 2017 | DHR Danaher Corp /de/ | Comas Daniel L | EVP &CFO | Sell | 10,250 | $86.09 | $882,443.00 | -6.1% | |
| Feb 27, 2017 | EXAS Exact Sciences Corp | Coward D Scott77 | SVP And General Counsel | Sell | 7,046 | $21.48 | $151,348.08 | -13.1% | |
| Feb 27, 2017 | EXAS Exact Sciences Corp | Arora Maneesh | COO | Sell | 11,114 | $21.50 | $238,968.30 | -1.0% | |
| Feb 27, 2017 | EXAS Exact Sciences Corp | Conroy Kevin T81 | President And CEO | Sell | 27,134 | $21.51 | $583,520.25 | -1.7% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.